Global Chronic Low Back Pain (CLBP) Treatment Market 2023-2030

Description

List of Tables

Global Chronic Low Back Pain (CLBP) Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Analgesic Medications, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Online and Offline), and by End-User (Hospitals, Orthopedic Clinic, Ambulatory Surgery Centers, and Others) Forecast Period (2023-2030)

The CLBP treatment market is anticipated to grow at a considerable CAGR of 4.8% during the forecast period. CLBP is a significant health issue globally, with numerous key drivers contributing to its prevalence. Some of the key factors includes obesity, injury, occupational hazards, psychological and genetic disorders are driving the CLBP instances globally.

However, the serious adverse effects of CLBP medications and negligence regarding the occurrence and complications of CLBP may limit the revenue growth of the market, owing to the excessive abuse of opioid. According to the National Institute on Drug Abuse (NIDA), approximately 21 to 29% of patients who are prescribed opioids for chronic pain misuse them, and up to 12% develop an opioid use disorder. Furthermore, NIDA states that opioid overdose deaths have increased by over five times since 1999, and in 2019 alone, there were over 49,000 opioid-related overdose deaths in the US.

However, it also presents an opportunity for manufacturers of chronic low back pain medications. With such a significant percentage of individuals misusing their prescribed opioids and developing opioid use disorder, there is a clear need for alternative treatment options for chronic pain management. This presents an opportunity for manufacturers to develop and produce non-opioid medications that can effectively manage chronic low back pain without the risk of addiction or misuse. By addressing this critical requirement, manufacturers can not only improve the lives of those suffering from chronic pain but also contribute to combatting the opioid epidemic. For instance, in December 2020, a new formulation of meloxicam (Qmiiz ODT) was approved by the FDA, is an NSAIDs manufactured by Lupin Ltd. This is an orally disintegrating tablet that rapidly dissolves in the mouth without the required water.

Segmental Outlook

The chronic low back pain treatment market is segmented based on treatment type, distribution channels, and end-user. Based on treatment type, the market is sub-segmented into analgesic medications, NSAIDs, anticonvulsants, antidepressants, and other medications such as muscle relaxants (cyclobenzaprine and tizanidine) that can reduce muscle spasms and tension. Based on the distribution channel, the market is categorized into online and offline. Based on distribution channel market is sub segmented into hospitals, orthopedic clinic, ambulatory surgery centers, and others (educational institution). Among these,

The online sub-segment is expected to cater to a prominent share of the market. The growth of e-commerce platforms and the increasing internet penetration has led to a surge in online sales in the pharmaceutical industry. This has paved the way for various online pharmacies to offer rapid delivery of prescription drugs. For instance, in November 2020, Walgreens extended its Same Day Delivery service to operate 24 hours a day, seven days a week across markets in the US. In addition, the company has launched Pickup in as little as 30 minutes in-store, via drive-thru and curbside, along with same day delivery in as little as one hour. As part of its continued efforts to enhance the customer experience, Walgreens is currently piloting a 30-Minute Pickup Guarantee in New Mexico, Oklahoma, and select Texas markets, covering the cost of shoppers' baskets if the order is not ready for pickup within 30 minutes.

Regional Outlooks

The global chronic low back pain (CLBP) treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The North America region is anticipated to witness considerable growth in the market. Increasing funding by regulatory bodies for the healthcare sector and advanced healthcare infrastructure is driving market growth. For instance, as per the report by the American Chiropractic Association, US spends approximately $50 billion each year on healthcare for low-back pain.

Global Chronic Low Back Pain (CLBP) Treatment Market Growth, by Region 2023-2030

Source: OMR Analysis

The North America Region Leads in the Global Chronic Low Back Pain (CLBP) Treatment Market

The North America region is anticipated to hold a prominent market share in the market. The growth is mainly attributed to aging population, sedentary lifestyles, and increasing health-related problems such as obesity and chronic diseases. Also, the growing investment by the government to strengthen the health infrastructure is anticipated to propel the demand for the CLBP treatment market. For instance, the US spent $4,255 billion on health care in 2021 which include Physician services, Prescription drugs and other personal health care costs.

Market Players Outlook

The chronic low back pain treatment market is a highly competitive arena, with several major players are focused on developing innovative strategies to differentiate themselves from their competitors and gain a larger share of the market. Johnson & Johnson Services Inc, Pfizer Inc., Sanofi S.A., Endo Pharmaceuticals Inc., and Koninklijke Philips N.V. are some of the players in this market. These companies are continuously improving the performance of chronic low back pain treatment by investing in research and development, as well as through strategic partnerships and acquisitions. For instance, in February 2021, Mesoblast ltd. Announced positive results from a Phase 3 trial of its allogeneic cellular therapy rexlemestrocel-L for chronic low back pain due to degenerative disc disease. The trial enrolled 404 patients who were refractory to conventional treatments, and the results showed that a single injection of the therapy may provide a safe and effective opioid-sparing treatment.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the chronic low back pain (CLBP) treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027308

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Endo Pharmaceuticals Inc.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Johnson & Johnson Services Inc.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Koninklijke Philips N.V.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Pfizer Inc.
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Sanofi S.A.
- 3.6.1. Overview
- 3.6.2. Financial Analysis
- 3.6.3. SWOT Analysis
- 3.6.4. Recent Developments
3.7. Key Strategy Analysis

4. Market Segmentation

4.1. Global Chronic Low Back Pain (CLBP) Treatment Market by Treatment Type
- 4.1.1. Analgesic Medications
- 4.1.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 4.1.3. Anticonvulsants
- 4.1.4. Antidepressants
- 4.1.5. Others (Muscle Relaxants)
4.2. Global Chronic Low Back Pain (CLBP)Treatment Market by Distribution Channel
- 4.2.1. Online
- 4.2.2. Offline
4.3. Global Chronic Low Back Pain (CLBP)Treatment Market by End-User
- 4.3.1. Hospitals
- 4.3.2. Orthopedic Clinic
- 4.3.3. Ambulatory Surgery Centers
- 4.3.4. Others (Educational institution)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abbott Laboratories
6.2. Actiza Pharmaceuticals Pvt. Ltd.
6.3. AstraZeneca PLC
6.4. Becton, Dickinson, and Co.
6.5. Bio Wave Corp.
6.6. Boston Scientific Corp.
6.7. Bristol-Myers Squibb Co.
6.8. Eli Lilly and Co.
6.9. Endo Pharmaceuticals Inc.
6.10. GlaxoSmithKline plc
6.11. Johnson & Johnson Service Inc.
6.12. Koninklijke Philips N.V.
6.13. Lupin ltd.
6.14. Medtronic plc
6.15. Merck & Co., Inc.,
6.16. Novartis AG
6.17. Pfizer, Inc.
6.18. Sanofi S.A.
6.19. Takeda Pharmaceuticals
6.20. Vertebral Technologies Inc.